The role of mifepristone in managing myoma: a systematic review and meta-analysis of uterine parameters

Our analysis indicated that Mifepristone was associated with a non-significant reduction in uterine volume among patients with uterine myoma. However, higher daily doses (10 mg) demonstrated greater clinical benefits in relieving dyspareunia, despite minimal changes in uterine size. These findings suggest that higher doses (10 mg daily) may be a consideration for symptom relief, particularly for dyspareunia, despite minimal changes in uterine size. This suggestion is preliminary, given the non-significant primary outcomes and low certainty of evidence for key comparisons.